APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Influenzavirus B Infection Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Influenzavirus B Infection Drug Market Analysis and Forecast 2026-2032

Report ID 174002720219 December 2025216 pages

Choose your research edition.

Industry ResearchInfluenzavirus B Infection Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenzavirus B Infection Drug Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Influenzavirus B Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenzavirus B Infection Drug Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenzavirus B Infection Drug Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Influenzavirus B Infection Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Influenzavirus B Infection Drug include Sanofi, AbbVie Inc, Vectura Group Plc, Vaxart Inc, TSRL Inc, SK Chemicals Co Ltd, Shionogi & Co Ltd, Sanofi Pasteur SA and Romark Laboratories LC, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Influenzavirus B Infection Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Influenzavirus B Infection Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Influenzavirus B Infection Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Influenzavirus B Infection Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Influenzavirus B Infection Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Influenzavirus B Infection Drug sales, projected growth trends, production technology, application and end-user industry.

Influenzavirus B Infection Drug Segment by Company

Sanofi

AbbVie Inc

Vectura Group Plc

Vaxart Inc

TSRL Inc

SK Chemicals Co Ltd

Shionogi & Co Ltd

Sanofi Pasteur SA

Romark Laboratories LC

Park Active Molecules

Novavax Inc

Mucosis BV

MedImmune LLC

Medicago Inc

Kineta Inc

Inovio Pharmaceuticals Inc

Green Cross Corp

GlaxoSmithKline Plc

Fujifilm Holdings Corporation

Daiichi Sankyo Company Ltd

ContraFect Corp

Cadila Healthcare Ltd

BioCryst Pharmaceuticals Inc

Aphios Corp

Amarillo Biosciences Inc

Altravax Inc

Adimmune Corp

Influenzavirus B Infection Drug Segment by Type

KIN-1400

GC-3106A

CF-403

APP-309

Others

Influenzavirus B Infection Drug Segment by Application

Clinic

Hospital

Others

Influenzavirus B Infection Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenzavirus B Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenzavirus B Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenzavirus B Infection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Influenzavirus B Infection Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Influenzavirus B Infection Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Influenzavirus B Infection Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Influenzavirus B Infection Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. KIN-1400 Major Manufacturers Table 3. GC-3106A Major Manufacturers Table 4. CF-403 Major Manufacturers Table 5. APP-309 Major Manufacturers Table 6. Others Major Manufacturers Table 7. Global Influenzavirus B Infection Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Clinic Major Manufacturers Table 9. Hospital Major Manufacturers Table 10. Others Major Manufacturers Table 11. Influenzavirus B Infection Drug Industry Trends Table 12. Influenzavirus B Infection Drug Industry Drivers Table 13. Influenzavirus B Infection Drug Industry Opportunities and Challenges Table 14. Influenzavirus B Infection Drug Industry Restraints Table 15. Global Influenzavirus B Infection Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Influenzavirus B Infection Drug Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Influenzavirus B Infection Drug Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2021-2026) Table 19. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2027-2032) Table 20. Global Influenzavirus B Infection Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Influenzavirus B Infection Drug Sales by Region (2021-2026) & (K Units) Table 22. Global Influenzavirus B Infection Drug Sales by Region (2027-2032) & (K Units) Table 23. Global Influenzavirus B Infection Drug Sales Market Share by Region (2021-2026) Table 24. Global Influenzavirus B Infection Drug Sales Market Share by Region (2027-2032) Table 25. Global Influenzavirus B Infection Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Influenzavirus B Infection Drug Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Influenzavirus B Infection Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Influenzavirus B Infection Drug Sales Market Share by Manufacturers (2021-2026) Table 29. Global Influenzavirus B Infection Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Influenzavirus B Infection Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Influenzavirus B Infection Drug Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Influenzavirus B Infection Drug Manufacturers, Product Type & Application Table 33. Global Influenzavirus B Infection Drug Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Influenzavirus B Infection Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Influenzavirus B Infection Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Influenzavirus B Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Influenzavirus B Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2021-2026) Table 40. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2027-2032) Table 41. Global Influenzavirus B Infection Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 43. Global Influenzavirus B Infection Drug Sales by Type (2027-2032) & (K Units) Table 44. Global Influenzavirus B Infection Drug Sales Market Share by Type (2021-2026) Table 45. Global Influenzavirus B Infection Drug Sales Market Share by Type (2027-2032) Table 46. Global Influenzavirus B Infection Drug Price by Type (2021-2026) & (US$/Unit) Table 47. Global Influenzavirus B Infection Drug Price by Type (2027-2032) & (US$/Unit) Table 48. Global Influenzavirus B Infection Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Influenzavirus B Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Influenzavirus B Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2021-2026) Table 52. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2027-2032) Table 53. Global Influenzavirus B Infection Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 55. Global Influenzavirus B Infection Drug Sales by Application (2027-2032) & (K Units) Table 56. Global Influenzavirus B Infection Drug Sales Market Share by Application (2021-2026) Table 57. Global Influenzavirus B Infection Drug Sales Market Share by Application (2027-2032) Table 58. Global Influenzavirus B Infection Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Influenzavirus B Infection Drug Price by Application (2027-2032) & (US$/Unit) Table 60. Sanofi Company Information Table 61. Sanofi Business Overview Table 62. Sanofi Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Sanofi Influenzavirus B Infection Drug Product Portfolio Table 64. Sanofi Recent Development Table 65. AbbVie Inc Company Information Table 66. AbbVie Inc Business Overview Table 67. AbbVie Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. AbbVie Inc Influenzavirus B Infection Drug Product Portfolio Table 69. AbbVie Inc Recent Development Table 70. Vectura Group Plc Company Information Table 71. Vectura Group Plc Business Overview Table 72. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio Table 74. Vectura Group Plc Recent Development Table 75. Vaxart Inc Company Information Table 76. Vaxart Inc Business Overview Table 77. Vaxart Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Vaxart Inc Influenzavirus B Infection Drug Product Portfolio Table 79. Vaxart Inc Recent Development Table 80. TSRL Inc Company Information Table 81. TSRL Inc Business Overview Table 82. TSRL Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. TSRL Inc Influenzavirus B Infection Drug Product Portfolio Table 84. TSRL Inc Recent Development Table 85. SK Chemicals Co Ltd Company Information Table 86. SK Chemicals Co Ltd Business Overview Table 87. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio Table 89. SK Chemicals Co Ltd Recent Development Table 90. Shionogi & Co Ltd Company Information Table 91. Shionogi & Co Ltd Business Overview Table 92. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio Table 94. Shionogi & Co Ltd Recent Development Table 95. Sanofi Pasteur SA Company Information Table 96. Sanofi Pasteur SA Business Overview Table 97. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio Table 99. Sanofi Pasteur SA Recent Development Table 100. Romark Laboratories LC Company Information Table 101. Romark Laboratories LC Business Overview Table 102. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio Table 104. Romark Laboratories LC Recent Development Table 105. Park Active Molecules Company Information Table 106. Park Active Molecules Business Overview Table 107. Park Active Molecules Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Park Active Molecules Influenzavirus B Infection Drug Product Portfolio Table 109. Park Active Molecules Recent Development Table 110. Novavax Inc Company Information Table 111. Novavax Inc Business Overview Table 112. Novavax Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Novavax Inc Influenzavirus B Infection Drug Product Portfolio Table 114. Novavax Inc Recent Development Table 115. Mucosis BV Company Information Table 116. Mucosis BV Business Overview Table 117. Mucosis BV Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Mucosis BV Influenzavirus B Infection Drug Product Portfolio Table 119. Mucosis BV Recent Development Table 120. MedImmune LLC Company Information Table 121. MedImmune LLC Business Overview Table 122. MedImmune LLC Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. MedImmune LLC Influenzavirus B Infection Drug Product Portfolio Table 124. MedImmune LLC Recent Development Table 125. Medicago Inc Company Information Table 126. Medicago Inc Business Overview Table 127. Medicago Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Medicago Inc Influenzavirus B Infection Drug Product Portfolio Table 129. Medicago Inc Recent Development Table 130. Kineta Inc Company Information Table 131. Kineta Inc Business Overview Table 132. Kineta Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Kineta Inc Influenzavirus B Infection Drug Product Portfolio Table 134. Kineta Inc Recent Development Table 135. Inovio Pharmaceuticals Inc Company Information Table 136. Inovio Pharmaceuticals Inc Business Overview Table 137. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio Table 139. Inovio Pharmaceuticals Inc Recent Development Table 140. Green Cross Corp Company Information Table 141. Green Cross Corp Business Overview Table 142. Green Cross Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Green Cross Corp Influenzavirus B Infection Drug Product Portfolio Table 144. Green Cross Corp Recent Development Table 145. GlaxoSmithKline Plc Company Information Table 146. GlaxoSmithKline Plc Business Overview Table 147. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio Table 149. GlaxoSmithKline Plc Recent Development Table 150. Fujifilm Holdings Corporation Company Information Table 151. Fujifilm Holdings Corporation Business Overview Table 152. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio Table 154. Fujifilm Holdings Corporation Recent Development Table 155. Daiichi Sankyo Company Ltd Company Information Table 156. Daiichi Sankyo Company Ltd Business Overview Table 157. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio Table 159. Daiichi Sankyo Company Ltd Recent Development Table 160. ContraFect Corp Company Information Table 161. ContraFect Corp Business Overview Table 162. ContraFect Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. ContraFect Corp Influenzavirus B Infection Drug Product Portfolio Table 164. ContraFect Corp Recent Development Table 165. Cadila Healthcare Ltd Company Information Table 166. Cadila Healthcare Ltd Business Overview Table 167. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 168. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio Table 169. Cadila Healthcare Ltd Recent Development Table 170. BioCryst Pharmaceuticals Inc Company Information Table 171. BioCryst Pharmaceuticals Inc Business Overview Table 172. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 173. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio Table 174. BioCryst Pharmaceuticals Inc Recent Development Table 175. Aphios Corp Company Information Table 176. Aphios Corp Business Overview Table 177. Aphios Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 178. Aphios Corp Influenzavirus B Infection Drug Product Portfolio Table 179. Aphios Corp Recent Development Table 180. Amarillo Biosciences Inc Company Information Table 181. Amarillo Biosciences Inc Business Overview Table 182. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 183. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio Table 184. Amarillo Biosciences Inc Recent Development Table 185. Altravax Inc Company Information Table 186. Altravax Inc Business Overview Table 187. Altravax Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 188. Altravax Inc Influenzavirus B Infection Drug Product Portfolio Table 189. Altravax Inc Recent Development Table 190. Adimmune Corp Company Information Table 191. Adimmune Corp Business Overview Table 192. Adimmune Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 193. Adimmune Corp Influenzavirus B Infection Drug Product Portfolio Table 194. Adimmune Corp Recent Development Table 195. North America Influenzavirus B Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 196. North America Influenzavirus B Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 197. North America Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 198. North America Influenzavirus B Infection Drug Sales by Type (2027-2032) & (K Units) Table 199. North America Influenzavirus B Infection Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 200. North America Influenzavirus B Infection Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 201. North America Influenzavirus B Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 202. North America Influenzavirus B Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 203. North America Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 204. North America Influenzavirus B Infection Drug Sales by Application (2027-2032) & (K Units) Table 205. North America Influenzavirus B Infection Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 206. North America Influenzavirus B Infection Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 207. North America Influenzavirus B Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 208. North America Influenzavirus B Infection Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 209. North America Influenzavirus B Infection Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 210. North America Influenzavirus B Infection Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 211. North America Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 212. North America Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 213. North America Influenzavirus B Infection Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 214. North America Influenzavirus B Infection Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 215. United States Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 216. Canada Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 217. Europe Influenzavirus B Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 218. Europe Influenzavirus B Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 219. Europe Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 220. Europe Influenzavirus B Infection Drug Sales by Type (2027-2032) & (K Units) Table 221. Europe Influenzavirus B Infection Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 222. Europe Influenzavirus B Infection Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 223. Europe Influenzavirus B Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 224. Europe Influenzavirus B Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 225. Europe Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 226. Europe Influenzavirus B Infection Drug Sales by Application (2027-2032) & (K Units) Table 227. Europe Influenzavirus B Infection Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 228. Europe Influenzavirus B Infection Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 229. Europe Influenzavirus B Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 230. Europe Influenzavirus B Infection Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 231. Europe Influenzavirus B Infection Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 232. Europe Influenzavirus B Infection Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 233. Europe Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 234. Europe Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 235. Europe Influenzavirus B Infection Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 236. Europe Influenzavirus B Infection Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 237. Germany Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 238. France Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 239. U.K. Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 240. Italy Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 241. Netherlands Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 242. China Influenzavirus B Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 243. China Influenzavirus B Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 244. China Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 245. China Influenzavirus B Infection Drug Sales by Type (2027-2032) & (K Units) Table 246. China Influenzavirus B Infection Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 247. China Influenzavirus B Infection Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 248. China Influenzavirus B Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 249. China Influenzavirus B Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 250. China Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 251. China Influenzavirus B Infection Drug Sales by Application (2027-2032) & (K Units) Table 252. China Influenzavirus B Infection Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 253. China Influenzavirus B Infection Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 254. Asia Influenzavirus B Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 255. Asia Influenzavirus B Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 256. Asia Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 257. Asia Influenzavirus B Infection Drug Sales by Type (2027-2032) & (K Units) Table 258. Asia Influenzavirus B Infection Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 259. Asia Influenzavirus B Infection Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 260. Asia Influenzavirus B Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 261. Asia Influenzavirus B Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 262. Asia Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 263. Asia Influenzavirus B Infection Drug Sales by Application (2027-2032) & (K Units) Table 264. Asia Influenzavirus B Infection Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 265. Asia Influenzavirus B Infection Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 266. Asia Influenzavirus B Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 267. Asia Influenzavirus B Infection Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 268. Asia Influenzavirus B Infection Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 269. Asia Influenzavirus B Infection Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 270. Asia Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 271. Asia Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 272. Asia Influenzavirus B Infection Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 273. Asia Influenzavirus B Infection Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 274. Japan Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 275. South Korea Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 276. India Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 277. Australia Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 278. China Taiwan Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 279. Southeast Asia Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 280. SAMEA Influenzavirus B Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 281. SAMEA Influenzavirus B Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 282. SAMEA Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 283. SAMEA Influenzavirus B Infection Drug Sales by Type (2027-2032) & (K Units) Table 284. SAMEA Influenzavirus B Infection Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 285. SAMEA Influenzavirus B Infection Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 286. SAMEA Influenzavirus B Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 287. SAMEA Influenzavirus B Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 288. SAMEA Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 289. SAMEA Influenzavirus B Infection Drug Sales by Application (2027-2032) & (K Units) Table 290. SAMEA Influenzavirus B Infection Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 291. SAMEA Influenzavirus B Infection Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 292. SAMEA Influenzavirus B Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 293. SAMEA Influenzavirus B Infection Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 294. SAMEA Influenzavirus B Infection Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 295. SAMEA Influenzavirus B Infection Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 296. SAMEA Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 297. SAMEA Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 298. SAMEA Influenzavirus B Infection Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 299. SAMEA Influenzavirus B Infection Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 300. Brazil Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 301. Argentina Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 302. Chile Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 303. Colombia Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 304. Peru Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 305. Saudi Arabia Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 306. Israel Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 307. UAE Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 308. Turkey Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 309. Iran Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 310. Egypt Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Table 311. Key Raw Materials Table 312. Raw Materials Key Suppliers Table 313. Influenzavirus B Infection Drug Distributors List Table 314. Influenzavirus B Infection Drug Customers List Table 315. Research Programs/Design for This Report Table 316. Authors List of This Report Table 317. Secondary Sources Table 318. Primary Sources List of Figures Figure 1. Influenzavirus B Infection Drug Image Figure 2. Global Influenzavirus B Infection Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenzavirus B Infection Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. KIN-1400 Image Figure 5. GC-3106A Image Figure 6. CF-403 Image Figure 7. APP-309 Image Figure 8. Others Image Figure 9. Global Influenzavirus B Infection Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Influenzavirus B Infection Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Clinic Image Figure 12. Hospital Image Figure 13. Others Image Figure 14. Global Influenzavirus B Infection Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Figure 16. Global Influenzavirus B Infection Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Influenzavirus B Infection Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2021-2032) Figure 19. Global Influenzavirus B Infection Drug Sales (2021-2032) & (K Units) Figure 20. Global Influenzavirus B Infection Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Influenzavirus B Infection Drug Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Influenzavirus B Infection Drug Sales YoY (2021-2032) & (K Units) Figure 23. Europe Influenzavirus B Infection Drug Sales YoY (2021-2032) & (K Units) Figure 24. China Influenzavirus B Infection Drug Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Influenzavirus B Infection Drug Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Influenzavirus B Infection Drug Sales YoY (2021-2032) & (K Units) Figure 27. Global Influenzavirus B Infection Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Influenzavirus B Infection Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Influenzavirus B Infection Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Influenzavirus B Infection Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2021-2032) Figure 33. Global Influenzavirus B Infection Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Influenzavirus B Infection Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Influenzavirus B Infection Drug Sales Market Share by Type (2021-2032) Figure 36. Global Influenzavirus B Infection Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Influenzavirus B Infection Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2021-2032) Figure 39. Global Influenzavirus B Infection Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Influenzavirus B Infection Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Influenzavirus B Infection Drug Sales Market Share by Application (2021-2032) Figure 42. North America Influenzavirus B Infection Drug Revenue Share by Type (2021-2032) Figure 43. North America Influenzavirus B Infection Drug Sales Share by Type (2021-2032) Figure 44. North America Influenzavirus B Infection Drug Revenue Share by Application (2021-2032) Figure 45. North America Influenzavirus B Infection Drug Sales Share by Application (2021-2032) Figure 46. North America Influenzavirus B Infection Drug Revenue Share by Country (2021-2032) Figure 47. North America Influenzavirus B Infection Drug Sales Share by Country (2021-2032) Figure 48. Europe Influenzavirus B Infection Drug Revenue Share by Type (2021-2032) Figure 49. Europe Influenzavirus B Infection Drug Sales Share by Type (2021-2032) Figure 50. Europe Influenzavirus B Infection Drug Revenue Share by Application (2021-2032) Figure 51. Europe Influenzavirus B Infection Drug Sales Share by Application (2021-2032) Figure 52. Europe Influenzavirus B Infection Drug Revenue Share by Country (2021-2032) Figure 53. Europe Influenzavirus B Infection

Scope & coverage.

Types
  • KIN-1400
  • GC-3106A
  • CF-403
  • APP-309
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Sanofi
  • AbbVie Inc
  • Vectura Group Plc
  • Vaxart Inc
  • TSRL Inc
  • SK Chemicals Co Ltd
  • Shionogi & Co Ltd
  • Sanofi Pasteur SA
  • Romark Laboratories LC
  • Park Active Molecules
  • Novavax Inc
  • Mucosis BV
  • MedImmune LLC
  • Medicago Inc
  • Kineta Inc
  • Inovio Pharmaceuticals Inc
  • Green Cross Corp
  • GlaxoSmithKline Plc
  • Fujifilm Holdings Corporation
  • Daiichi Sankyo Company Ltd
  • ContraFect Corp
  • Cadila Healthcare Ltd
  • BioCryst Pharmaceuticals Inc
  • Aphios Corp
  • Amarillo Biosciences Inc
  • Altravax Inc
  • Adimmune Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Influenzavirus B Infection Drug Market by Type
  3. 1.2.1 Global Influenzavirus B Infection Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 KIN-1400
  5. 1.2.3 GC-3106A
  6. 1.2.4 CF-403
  7. 1.2.5 APP-309
  8. 1.2.6 Others
  9. 1.3 Influenzavirus B Infection Drug Market by Application
  10. 1.3.1 Global Influenzavirus B Infection Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Clinic
  12. 1.3.3 Hospital
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Influenzavirus B Infection Drug Market Dynamics
  1. 2.1 Influenzavirus B Infection Drug Industry Trends
  2. 2.2 Influenzavirus B Infection Drug Industry Drivers
  3. 2.3 Influenzavirus B Infection Drug Industry Opportunities and Challenges
  4. 2.4 Influenzavirus B Infection Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Influenzavirus B Infection Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Influenzavirus B Infection Drug Revenue by Region
  3. 3.2.1 Global Influenzavirus B Infection Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Influenzavirus B Infection Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Influenzavirus B Infection Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Influenzavirus B Infection Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Influenzavirus B Infection Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Influenzavirus B Infection Drug Sales by Region
  9. 3.4.1 Global Influenzavirus B Infection Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Influenzavirus B Infection Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Influenzavirus B Infection Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Influenzavirus B Infection Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Influenzavirus B Infection Drug Revenue by Manufacturers
  2. 4.1.1 Global Influenzavirus B Infection Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Influenzavirus B Infection Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Influenzavirus B Infection Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Influenzavirus B Infection Drug Sales by Manufacturers
  6. 4.2.1 Global Influenzavirus B Infection Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Influenzavirus B Infection Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Influenzavirus B Infection Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Influenzavirus B Infection Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Influenzavirus B Infection Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Influenzavirus B Infection Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Influenzavirus B Infection Drug Manufacturers, Product Type & Application
  13. 4.7 Global Influenzavirus B Infection Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Influenzavirus B Infection Drug Market CR5 and HHI
  16. 4.8.2 2025 Influenzavirus B Infection Drug Tier 1, Tier 2, and Tier 3
5 Influenzavirus B Infection Drug Market by Type
  1. 5.1 Global Influenzavirus B Infection Drug Revenue by Type
  2. 5.1.1 Global Influenzavirus B Infection Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Influenzavirus B Infection Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Influenzavirus B Infection Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Influenzavirus B Infection Drug Sales by Type
  6. 5.2.1 Global Influenzavirus B Infection Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Influenzavirus B Infection Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Influenzavirus B Infection Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Influenzavirus B Infection Drug Price by Type
6 Influenzavirus B Infection Drug Market by Application
  1. 6.1 Global Influenzavirus B Infection Drug Revenue by Application
  2. 6.1.1 Global Influenzavirus B Infection Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Influenzavirus B Infection Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Influenzavirus B Infection Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Influenzavirus B Infection Drug Sales by Application
  6. 6.2.1 Global Influenzavirus B Infection Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Influenzavirus B Infection Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Influenzavirus B Infection Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Influenzavirus B Infection Drug Price by Application
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Influenzavirus B Infection Drug Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 AbbVie Inc
  8. 7.2.1 AbbVie Inc Company Information
  9. 7.2.2 AbbVie Inc Business Overview
  10. 7.2.3 AbbVie Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 AbbVie Inc Influenzavirus B Infection Drug Product Portfolio
  12. 7.2.5 AbbVie Inc Recent Developments
  13. 7.3 Vectura Group Plc
  14. 7.3.1 Vectura Group Plc Company Information
  15. 7.3.2 Vectura Group Plc Business Overview
  16. 7.3.3 Vectura Group Plc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio
  18. 7.3.5 Vectura Group Plc Recent Developments
  19. 7.4 Vaxart Inc
  20. 7.4.1 Vaxart Inc Company Information
  21. 7.4.2 Vaxart Inc Business Overview
  22. 7.4.3 Vaxart Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Vaxart Inc Influenzavirus B Infection Drug Product Portfolio
  24. 7.4.5 Vaxart Inc Recent Developments
  25. 7.5 TSRL Inc
  26. 7.5.1 TSRL Inc Company Information
  27. 7.5.2 TSRL Inc Business Overview
  28. 7.5.3 TSRL Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 TSRL Inc Influenzavirus B Infection Drug Product Portfolio
  30. 7.5.5 TSRL Inc Recent Developments
  31. 7.6 SK Chemicals Co Ltd
  32. 7.6.1 SK Chemicals Co Ltd Company Information
  33. 7.6.2 SK Chemicals Co Ltd Business Overview
  34. 7.6.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio
  36. 7.6.5 SK Chemicals Co Ltd Recent Developments
  37. 7.7 Shionogi & Co Ltd
  38. 7.7.1 Shionogi & Co Ltd Company Information
  39. 7.7.2 Shionogi & Co Ltd Business Overview
  40. 7.7.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio
  42. 7.7.5 Shionogi & Co Ltd Recent Developments
  43. 7.8 Sanofi Pasteur SA
  44. 7.8.1 Sanofi Pasteur SA Company Information
  45. 7.8.2 Sanofi Pasteur SA Business Overview
  46. 7.8.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio
  48. 7.8.5 Sanofi Pasteur SA Recent Developments
  49. 7.9 Romark Laboratories LC
  50. 7.9.1 Romark Laboratories LC Company Information
  51. 7.9.2 Romark Laboratories LC Business Overview
  52. 7.9.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio
  54. 7.9.5 Romark Laboratories LC Recent Developments
  55. 7.10 Park Active Molecules
  56. 7.10.1 Park Active Molecules Company Information
  57. 7.10.2 Park Active Molecules Business Overview
  58. 7.10.3 Park Active Molecules Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Park Active Molecules Influenzavirus B Infection Drug Product Portfolio
  60. 7.10.5 Park Active Molecules Recent Developments
  61. 7.11 Novavax Inc
  62. 7.11.1 Novavax Inc Company Information
  63. 7.11.2 Novavax Inc Business Overview
  64. 7.11.3 Novavax Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Novavax Inc Influenzavirus B Infection Drug Product Portfolio
  66. 7.11.5 Novavax Inc Recent Developments
  67. 7.12 Mucosis BV
  68. 7.12.1 Mucosis BV Company Information
  69. 7.12.2 Mucosis BV Business Overview
  70. 7.12.3 Mucosis BV Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Mucosis BV Influenzavirus B Infection Drug Product Portfolio
  72. 7.12.5 Mucosis BV Recent Developments
  73. 7.13 MedImmune LLC
  74. 7.13.1 MedImmune LLC Company Information
  75. 7.13.2 MedImmune LLC Business Overview
  76. 7.13.3 MedImmune LLC Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 MedImmune LLC Influenzavirus B Infection Drug Product Portfolio
  78. 7.13.5 MedImmune LLC Recent Developments
  79. 7.14 Medicago Inc
  80. 7.14.1 Medicago Inc Company Information
  81. 7.14.2 Medicago Inc Business Overview
  82. 7.14.3 Medicago Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Medicago Inc Influenzavirus B Infection Drug Product Portfolio
  84. 7.14.5 Medicago Inc Recent Developments
  85. 7.15 Kineta Inc
  86. 7.15.1 Kineta Inc Company Information
  87. 7.15.2 Kineta Inc Business Overview
  88. 7.15.3 Kineta Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Kineta Inc Influenzavirus B Infection Drug Product Portfolio
  90. 7.15.5 Kineta Inc Recent Developments
  91. 7.16 Inovio Pharmaceuticals Inc
  92. 7.16.1 Inovio Pharmaceuticals Inc Company Information
  93. 7.16.2 Inovio Pharmaceuticals Inc Business Overview
  94. 7.16.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
  96. 7.16.5 Inovio Pharmaceuticals Inc Recent Developments
  97. 7.17 Green Cross Corp
  98. 7.17.1 Green Cross Corp Company Information
  99. 7.17.2 Green Cross Corp Business Overview
  100. 7.17.3 Green Cross Corp Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Green Cross Corp Influenzavirus B Infection Drug Product Portfolio
  102. 7.17.5 Green Cross Corp Recent Developments
  103. 7.18 GlaxoSmithKline Plc
  104. 7.18.1 GlaxoSmithKline Plc Company Information
  105. 7.18.2 GlaxoSmithKline Plc Business Overview
  106. 7.18.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio
  108. 7.18.5 GlaxoSmithKline Plc Recent Developments
  109. 7.19 Fujifilm Holdings Corporation
  110. 7.19.1 Fujifilm Holdings Corporation Company Information
  111. 7.19.2 Fujifilm Holdings Corporation Business Overview
  112. 7.19.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio
  114. 7.19.5 Fujifilm Holdings Corporation Recent Developments
  115. 7.20 Daiichi Sankyo Company Ltd
  116. 7.20.1 Daiichi Sankyo Company Ltd Company Information
  117. 7.20.2 Daiichi Sankyo Company Ltd Business Overview
  118. 7.20.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio
  120. 7.20.5 Daiichi Sankyo Company Ltd Recent Developments
  121. 7.21 ContraFect Corp
  122. 7.21.1 ContraFect Corp Company Information
  123. 7.21.2 ContraFect Corp Business Overview
  124. 7.21.3 ContraFect Corp Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 ContraFect Corp Influenzavirus B Infection Drug Product Portfolio
  126. 7.21.5 ContraFect Corp Recent Developments
  127. 7.22 Cadila Healthcare Ltd
  128. 7.22.1 Cadila Healthcare Ltd Company Information
  129. 7.22.2 Cadila Healthcare Ltd Business Overview
  130. 7.22.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio
  132. 7.22.5 Cadila Healthcare Ltd Recent Developments
  133. 7.23 BioCryst Pharmaceuticals Inc
  134. 7.23.1 BioCryst Pharmaceuticals Inc Company Information
  135. 7.23.2 BioCryst Pharmaceuticals Inc Business Overview
  136. 7.23.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
  138. 7.23.5 BioCryst Pharmaceuticals Inc Recent Developments
  139. 7.24 Aphios Corp
  140. 7.24.1 Aphios Corp Company Information
  141. 7.24.2 Aphios Corp Business Overview
  142. 7.24.3 Aphios Corp Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Aphios Corp Influenzavirus B Infection Drug Product Portfolio
  144. 7.24.5 Aphios Corp Recent Developments
  145. 7.25 Amarillo Biosciences Inc
  146. 7.25.1 Amarillo Biosciences Inc Company Information
  147. 7.25.2 Amarillo Biosciences Inc Business Overview
  148. 7.25.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  149. 7.25.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio
  150. 7.25.5 Amarillo Biosciences Inc Recent Developments
  151. 7.26 Altravax Inc
  152. 7.26.1 Altravax Inc Company Information
  153. 7.26.2 Altravax Inc Business Overview
  154. 7.26.3 Altravax Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  155. 7.26.4 Altravax Inc Influenzavirus B Infection Drug Product Portfolio
  156. 7.26.5 Altravax Inc Recent Developments
  157. 7.27 Adimmune Corp
  158. 7.27.1 Adimmune Corp Company Information
  159. 7.27.2 Adimmune Corp Business Overview
  160. 7.27.3 Adimmune Corp Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  161. 7.27.4 Adimmune Corp Influenzavirus B Infection Drug Product Portfolio
  162. 7.27.5 Adimmune Corp Recent Developments
8 North America
  1. 8.1 North America Influenzavirus B Infection Drug Market Size by Type
  2. 8.1.1 North America Influenzavirus B Infection Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Influenzavirus B Infection Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Influenzavirus B Infection Drug Price by Type (2021-2032)
  5. 8.2 North America Influenzavirus B Infection Drug Market Size by Application
  6. 8.2.1 North America Influenzavirus B Infection Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Influenzavirus B Infection Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Influenzavirus B Infection Drug Price by Application (2021-2032)
  9. 8.3 North America Influenzavirus B Infection Drug Market Size by Country
  10. 8.3.1 North America Influenzavirus B Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Influenzavirus B Infection Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Influenzavirus B Infection Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Influenzavirus B Infection Drug Market Size by Type
  2. 9.1.1 Europe Influenzavirus B Infection Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Influenzavirus B Infection Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Influenzavirus B Infection Drug Price by Type (2021-2032)
  5. 9.2 Europe Influenzavirus B Infection Drug Market Size by Application
  6. 9.2.1 Europe Influenzavirus B Infection Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Influenzavirus B Infection Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Influenzavirus B Infection Drug Price by Application (2021-2032)
  9. 9.3 Europe Influenzavirus B Infection Drug Market Size by Country
  10. 9.3.1 Europe Influenzavirus B Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Influenzavirus B Infection Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Influenzavirus B Infection Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Influenzavirus B Infection Drug Market Size by Type
  2. 10.1.1 China Influenzavirus B Infection Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Influenzavirus B Infection Drug Sales by Type (2021-2032)
  4. 10.1.3 China Influenzavirus B Infection Drug Price by Type (2021-2032)
  5. 10.2 China Influenzavirus B Infection Drug Market Size by Application
  6. 10.2.1 China Influenzavirus B Infection Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Influenzavirus B Infection Drug Sales by Application (2021-2032)
  8. 10.2.3 China Influenzavirus B Infection Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Influenzavirus B Infection Drug Market Size by Type
  2. 11.1.1 Asia Influenzavirus B Infection Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Influenzavirus B Infection Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Influenzavirus B Infection Drug Price by Type (2021-2032)
  5. 11.2 Asia Influenzavirus B Infection Drug Market Size by Application
  6. 11.2.1 Asia Influenzavirus B Infection Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Influenzavirus B Infection Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Influenzavirus B Infection Drug Price by Application (2021-2032)
  9. 11.3 Asia Influenzavirus B Infection Drug Market Size by Country
  10. 11.3.1 Asia Influenzavirus B Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Influenzavirus B Infection Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Influenzavirus B Infection Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Influenzavirus B Infection Drug Market Size by Type
  2. 12.1.1 SAMEA Influenzavirus B Infection Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Influenzavirus B Infection Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Influenzavirus B Infection Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Influenzavirus B Infection Drug Market Size by Application
  6. 12.2.1 SAMEA Influenzavirus B Infection Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Influenzavirus B Infection Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Influenzavirus B Infection Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Influenzavirus B Infection Drug Market Size by Country
  10. 12.3.1 SAMEA Influenzavirus B Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Influenzavirus B Infection Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Influenzavirus B Infection Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Influenzavirus B Infection Drug Value Chain Analysis
  2. 13.1.1 Influenzavirus B Infection Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Influenzavirus B Infection Drug Production Mode & Process
  6. 13.2 Influenzavirus B Infection Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Influenzavirus B Infection Drug Distributors
  9. 13.2.3 Influenzavirus B Infection Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst